Osiris Therapeutics Announces Positive Results in Groundbreaking Stem Cell Trial to Treat Heart Disease Intravenous Therapy Resulted in Statistically Significant Improvement Over Placebo in Multiple ...

COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ: OSIR), today announced that the company has achieved a $15 million milestone payment from NuVasive (NASDAQ: NUVA) related to the sale ...

COLUMBIA, Md. -- Osiris Therapeutics, a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and ...

COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ: OSIR), today announced that it has successfully completed enrollment in a Phase 2 clinical trial evaluating Prochymal (remestemcel-L) ...

COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (NAS: OSIR) , the leading company focused on developing and marketing stem cell products to treat serious medical conditions, announced today ...

JDRF Partners with Osiris on a Phase II Trial to Evaluate an Immunomodulatory Cell Therapy Product For Type 1 Diabetes New York, NY – October 25, 2007 – The Juvenile Diabetes Research Foundation ...

PITTSBURGH, PA--(Marketwired - October 11, 2016) - Net Health, the leading provider of software solutions for specialized outpatient care, announced today that their partnership with Osiris ...

COLUMBIA, Md., March 12, 2019 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and ...

OSIRIS-REx's samples of asteroid Bennu will land at 10:55 a.m. EDT (1455 GMT), while the spacecraft itself heads to a new target. When you purchase through links on our site, we may earn an affiliate ...

COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (NASDAQ: OSIR), today announced that it has successfully completed enrollment in a Phase 2 clinical trial evaluating Prochymal (remestemcel-L ...